Skip to content

MDMA: all studies

Page 73 of 346: studies 721 to 730 of 3,454, newest first. Back to the MDMA overview

Research

Nonmedical prescription drug use among African Americans who use MDMA (ecstasy/molly): Implications for risk reduction.

Addictive Behaviors April 2018 Khary K. Rigg, Amanda Sharp

Recent data suggest that both nonmedical prescription drug and MDMA (ecstasy/molly) use have risen among African Americans. However, studies investigating these two forms of drug use among African Americans are rare. As a result, very little is known about African-American MDMA users and their nonmedical use of prescription medications. The primary goal of this study, therefore, was to describe...

MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections.

Neuropsychopharmacology March 2018 Manoj K. Doss, Jessica Weafer, David A Gallo et al.

The psychoactive drug ±3,4-methylenedioxymethamphetamine (MDMA) is increasingly used for its perceived emotional effects (eg, prosociality, empathy, psychotherapy), but surprisingly little research has been aimed at identifying the effect of the drug on emotional episodic memory in humans. Here, we report the first double-blind placebo-controlled study to examine the effects of MDMA on...

Deaths related to MDMA (ecstasy/molly): Prevalence, root causes, and harm reduction interventions

Journal of Substance Use February 20, 2018 Khary K. Rigg, Amanda Sharp 42 citations

Recent data show that MDMA (3,4 methylenedioxymethamphetamine) related deaths (MRDs) are on the rise in several countries. This rise in MRDs has caught the attention of public health officials and treatment practitioners. Although MDMA is not a new drug, misinformation regarding the root causes of MRDs is still widespread. For example, MRDs continue to be reported as “overdoses” in the media...

DOI: 10.1080/14659891.2018.1436607 (opens in new tab) MDMA Ecstasy Misinformation Psychological intervention +3

(±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Psychopharmacology February 2018 Elizabeth G Pitts, Daniel W Curry, Karly N Hampshire et al.

The use of (±)-3,4-methylenedioxymethamphetamine ((±)-MDMA) as an adjunct to psychotherapy in the treatment of psychiatric and behavioral disorders dates back over 50 years. Only in recent years have controlled and peer-reviewed preclinical and clinical studies lent support to (±)-MDMA's hypothesized clinical utility. However, the clinical utility of (±)-MDMA is potentially mitigated by a range...

“Ecstasy” to Addiction: Mechanisms and Reinforcing Effects of Three Synthetic Cathinone Analogs of MDMA

Neuropharmacology January 31, 2018 Sean B. Dolan, Zhenglan Chen, Renqi Huang et al.

ABSTRACT This study aimed to address the mechanisms and reinforcing effects of three synthetic cathinone analogs of MDMA commonly reported in “Ecstasy” formulations: methylone, butylone, and pentylone. Whole‐cell patch clamp techniques were used to assess the mechanism of each compound at the dopamine and serotonin transporters. Separate groups of rats were trained to discriminate...

Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter

Scientific Reports January 12, 2018 Kim P. C. Kuypers, Rafael de la Torre, Magı́ Farré et al. 12 citations

Abstract MDMA exerts its main effects via the serotonergic system and the serotonin transporter. The gene coding for this transporter determines the expression rate of the transporter. Previously it was shown that healthy individuals with the short allelic variant (‘ s -group’) of the 5-HTTLPR-polymorphism displayed more anxiety and negative mood, and had a lower transcriptional efficiency...

The Controversial Ecstasy of Sor María Teresa Aycinena

Alone at the Altar January 9, 2018 Brianna Leavitt-Alcántara

Chapter 5 explores the devotion and controversy surrounding Sor María Teresa Aycinena, a Carmelite nun, who in 1816 in the midst of the Independence wars, reportedly began to experience the stigmata, visions, mystical crucifixions, and miraculous images formed with the blood of her wounds. The powerful archbishop, priests, and lay devotees, many of them women, supported the Carmelite nun as a...

Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.

Journal of Contemporary Psychotherapy January 6, 2018 Sascha Thal, Miriam J. J. Lommen 59 citations

The present paper discusses the current literature with regard to substance-assisted psychotherapy with Methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD). The aim of the paper is to give a comprehensive overview of the development from MDMA's early application in psychotherapy to its present and future role in the treatment of PTSD. It is further attempted to...

Key interindividual determinants in MDMA pharmacodynamics

Expert Opinion on Drug Metabolism & Toxicology January 5, 2018 Esther Papaseit, Marta Torrens, Clara Pérez‐mañá et al. 20 citations

MDMA, 3,4-methylenedioxymethamphetamine, is a synthetic phenethylamine derivative with structural and pharmacological similarities to both amphetamines and mescaline. MDMA produces characteristic amphetamine-like actions (euphoria, well-being), increases empathy, and induces pro-social effects that seem to motivate its recreational consumption and provide a basis for its potential therapeutic...

Are the neurocognitive deficits associated with 3,4-methylenedioxymethamphetamine caused by statistical deficits in ecstasy research? A systematic review

Drug Science, Policy and Law 2018 Timothy Amoroso

There is growing concern that the majority of modern research may be comprised of false findings, which is partly attributed to unacceptable flexibility in data analyses. Here this issue is considered in the literature suggesting that MDMA (3,4-methylenedioxymethamphetamine) may be associated with neurocognitive deficits. Research suggests that increased exposure to ecstasy is associated with...